• About us
• Contact

Advertisement

Person › Details

Jacobus P. M. (Jack) Elands (Adcytherix SAS)

Elands, Jacobus P. M. (Jack) (Adcytherix 202406 CEO + Co-Founder before Emergence Tx + Blink Biomedical + Amakem)

 

	Organisation	Adcytherix SAS
	Former/major organisation	Emergence Therapeutics AG
	Group	Eli Lilly (Group)
	Product	antibody-drug conjugate (ADC)
	Product 2	AMA0076 (Amakem)

Record changed: 2024-06-17

Advertisement

More documents for Jacobus P. M. (Jack) Elands

• [1] Adcytherix SAS. (6/11/24). "Press Release: Adcytherix Launches with € 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates". Marseille....
• [2] Emergence Therapeutics AG. (9/6/22). "Press Release: Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal". Amsterdam & Duisburg....
• [3] Emergence Therapeutics AG. (12/7/21). "Press Release: Emergence Therapeutics Raises €87 Million Series A Financing to Advance Nectin-4 ADC". Duisburg....
• [4] Mablink Bioscience SAS. (10/21/21). "Press Release: Mablink Bioscience and Emergence Therapeutics Enter into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy". Lyon & Duisburg....
• [5] High-Tech Gründerfonds Management GmbH. (11/25/20). "Press Release: Emergence Therapeutics Announces a Bumped-up Follow-on Seed Round Financing"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.